Free Trial

DexCom (DXCM) Stock Forecast & Price Target

DexCom logo
$67.78 +1.75 (+2.65%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$67.86 +0.08 (+0.11%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
6
Buy
17

Based on 23 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 6 have given a hold rating, 14 have given a buy rating, and 3 have given a strong buy rating for DXCM.

Consensus Price Target

$97.42
43.73% Upside
According to the 23 analysts' twelve-month price targets for DexCom, the average price target is $97.42. The highest price target for DXCM is $115.00, while the lowest price target for DXCM is $85.00. The average price target represents a forecasted upside of 43.73% from the current price of $67.78.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Analyst Ratings Over Time

TypeCurrent Forecast
10/9/24 to 10/9/25
1 Month Ago
9/9/24 to 9/9/25
3 Months Ago
7/11/24 to 7/11/25
1 Year Ago
10/10/23 to 10/9/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
15 Buy rating(s)
11 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$97.42$99.89$98.50$110.69
Forecasted Upside43.73% Upside27.42% Upside18.15% Upside58.99% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DexCom Stock vs. The Competition

TypeDexComMedical CompaniesS&P 500
Consensus Rating Score
2.87
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside43.73% Upside1,097.42% Upside170.76% Upside
News Sentiment Rating
Positive News

See Recent DXCM News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C-)
10/7/2025Citigroup
3 of 5 stars
Joanne Wuensch
Joanne Wuensch
4 of 5 stars
Lower TargetBuy$105.00 ➝ $85.00+27.93%
10/1/2025The Goldman Sachs Group
3 of 5 stars
Kate McShane
Kate McShane
4 of 5 stars
Lower TargetBuy$104.00 ➝ $89.00+37.98%
9/29/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$106.00+60.27%
9/26/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$112.00 ➝ $90.00+31.77%
9/8/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
8/21/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00+22.44%
7/31/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy
7/31/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$90.00 ➝ $100.00+18.40%
7/31/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetStrong-Buy$99.00 ➝ $102.00+20.95%
7/31/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$105.00 ➝ $106.00+19.02%
7/30/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$93.00 ➝ $98.00+9.13%
7/16/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$95.00 ➝ $100.00+17.95%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$82.00 ➝ $89.00+4.30%
6/16/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$102.00+24.41%
3/21/2025Cfra Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
3/8/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
2/3/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$85.00 ➝ $115.00+32.44%
1/16/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/25/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$82.00 ➝ $86.00+16.55%
10/25/2024Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$120.00 ➝ $115.00+53.54%
10/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetNeutral$75.00 ➝ $85.00+15.66%
10/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$90.00 ➝ $87.00+19.10%
8/23/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$90.00 ➝ $100.00+38.35%
7/26/2024BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$156.00 ➝ $120.00+88.62%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:21 AM ET.


Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 5, 2025. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • The current stock price is around $80, which may present a buying opportunity for investors looking for growth in the medical device sector.
  • DexCom, Inc. specializes in continuous glucose monitoring systems, a growing market due to the increasing prevalence of diabetes, which could lead to higher demand for their products.
  • Recent insider trading activity indicates confidence in the company's future, as executives have been actively managing their stock positions.
  • The company has a strong focus on innovation, continuously developing advanced CGM systems that enhance patient care and improve health outcomes.
  • With a relatively low percentage of stock owned by insiders, there may be more room for institutional investors to enter, potentially driving up the stock price.

DexCom
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • Insider sales have occurred recently, with executives selling shares, which could signal a lack of confidence in the stock's short-term performance.
  • The company has seen a slight decrease in insider ownership, which may raise concerns about alignment between management and shareholder interests.
  • Market competition in the diabetes management space is intensifying, which could impact DexCom's market share and pricing power.
  • Recent stock performance has shown fluctuations, which may indicate volatility and risk for potential investors.
  • With only a small percentage of stock owned by insiders, there may be less incentive for management to prioritize shareholder value in decision-making.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $97.42, with a high forecast of $115.00 and a low forecast of $85.00.

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 6 hold ratings, 14 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.

According to analysts, DexCom's stock has a predicted upside of 43.73% based on their 12-month stock forecasts.

Over the previous 90 days, DexCom's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like DexCom more than other "medical" companies. The consensus rating for DexCom is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how DXCM compares to other companies.


This page (NASDAQ:DXCM) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners